Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Blood - United States
doi 10.1182/blood-2018-99-113840

Related search